Biogen announced an exclusive worldwide license to Vanqua Bio’s preclinical C5aR1 inhibitor, paying $70 million up front with up to $990 million in contingent payments. The deal hands Biogen development, manufacturing and global commercialization responsibilities while allowing Vanqua to concentrate on its neuroscience pipeline. Biogen framed the acquisition as a strategic move to expand its immunology portfolio around innate and adaptive pathways. Biogen cited preclinical data supporting progression to human trials and said it plans to seek FDA permission to begin clinical testing in 2027 if further studies remain positive. Vanqua’s CEO Jim Sullivan called Biogen “uniquely positioned” to advance the asset. Financial analysts noted the deal reduces Vanqua’s capital burden and accelerates Biogen’s broader shift into less risk-prone immunology areas.